Compare CVS Health Corp (CVS) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs D Wave Quantum Inc — how do they compare? CVS Health Corp trades at $86.62 (market cap $112.49B), while D Wave Quantum Inc trades at $14.91 (market cap $5.78B). The key difference: CVS Health Corp is far larger — about 19.5× D Wave Quantum Inc's market cap, and CVS Health Corp pays a 3.02% dividend while D Wave Quantum Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and D Wave Quantum Inc for 32 Days on average.
| CVS | QBTS | |
|---|---|---|
Market Cap | $112.49B | $5.78B |
Volume | 8,467,392 | 14,335,003 |
Sector | Health | Technology |
52-Week High | $110.60 | $44.78 |
52-Week Low | $70.08 | $12.98 |
Typical Hold Time | 83 Days | 32 Days |
Enterprise Value | $174.83B | $5.28B |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
QBTS (D-Wave Quantum Inc.) trades at $15.22, down 3.61% on the day, amid a bearish technical signal despite a 100% analyst buy rating with a consensus price target of $34.38. The company shows significant financial strain with a net income margin of -2,001.59% and negative cash flow from operations, though it maintains a high gross margin of 64.19%. Recent news highlights ongoing fraud investigations alongside technological advancements in quantum computing.
The stock presents high risk due to severe losses and cash burn, but offers speculative upside if the company can monetize its quantum technology. Investors face substantial volatility from operational challenges and legal scrutiny, requiring caution despite Wall Street optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
